Divi's Laboratories Q2: Brokerages Raise Target Prices Post-Results

Several major global financial institutions have revised their target prices upward for Divi's Laboratories following the company's second-quarter review. Firms like Goldman Sachs, Jefferies, and JPMorgan expressed optimism driven by upcoming contract development and manufacturing operations. Meanwhile, Kotak Institutional Equities chose to maintain a sell rating on the pharmaceutical stock amidst these varied market reactions.